Summary of Study ST001036

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000693. The data can be accessed directly via it's Project DOI: 10.21228/M83H4H This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)
Study IDST001036
Study TitleTCA Concentrations in Neuromyelitis Optica Patients (part - II)
Study SummaryPatients with an inflammatory disease of the central nervous system known as neuromyelitis optica (NMO) experience increased levels of depression. These patients have an antibody that recognizes a type of cell in the brain called astrocytes – binding of this antibody to astrocytes triggers a stress response in the cell that results in the development of brain lesions that cause disability and cognitive disturbances. We recently observed a change in the level of glutamate in a part of the brain involved in depression in patients with NMO. Glutamate is a chemical that is used in the brain for communication between neurons – reduced levels of glutamate are thought to trigger depression by reducing neuronal activity in specific circuits. Based on this observation and the known role of astrocytes in maintaining glutamate levels in the brain, we hypothesize that the NMO antibody disturbs metabolic activity in astrocytes and thereby reduces glutamate and triggers depression. We intend to measure TCA concentration in NMO astrocytes. It is our hope that we will not only learn something about the mechanisms of astrocyte dysregulation in neuromyelitis optica, but that we will learn something about the mechanisms of depression in general that may lead to new therapies for this disease.
Institute
Mayo Clinic
Last NameHowe
First NameCharles
Address200 First St. SW, Rochester, Minnesota, 55905, USA
Emailhowe@mayo.edu
Phone507-284-9288
Submit Date2018-08-13
Analysis Type DetailGC-MS
Release Date2020-08-20
Release Version1
Charles Howe Charles Howe
https://dx.doi.org/10.21228/M83H4H
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Time Point Matrix Condition
SA069331ms6982-560h Fresh Media BGP 50uMGt Gn
SA069332ms6923-210h Fresh Media BGP50uMGt Gn
SA069333ms6923-190h Fresh Media BGPGt 0.5 mM Gn
SA069334ms6982-540h Fresh Media BGPGt 0.5mM Gn
SA069335ms6923-200h Fresh Media BGPGt 5mM Gn
SA069336ms6982-550h Fresh Media BGPGt 5mM Gn
SA069337ms6982-570h Fresh Media E Med
SA069338ms6923-220h Fresh Media E Med
SA069339ms6982-531h nonCO2 Spent Sup BGP50uMGt Gn
SA069340ms6923-181h nonCO2 Spent Sup BGP50uMGt Gn
SA069341ms6982-521h nonCO2 Spent Sup BGP50uMGt Gn
SA069342ms6982-511h nonCO2 Spent Sup BGP50uMGt Gn
SA069343ms6923-161h nonCO2 Spent Sup BGP50uMGt Gn
SA069344ms6923-171h nonCO2 Spent Sup BGP50uMGt Gn
SA069345ms6923-101h nonCO2 Spent Sup BGPGt 0.5 mM Gn
SA069346ms6923-121h nonCO2 Spent Sup BGPGt 0.5 mM Gn
SA069347ms6923-111h nonCO2 Spent Sup BGPGt 0.5 mM Gn
SA069348ms6982-461h nonCO2 Spent Sup BGPGt 0.5mM Gn
SA069349ms6982-451h nonCO2 Spent Sup BGPGt 0.5mM Gn
SA069350ms6982-471h nonCO2 Spent Sup BGPGt 0.5mM Gn
SA069351ms6982-501h nonCO2 Spent Sup BGPGt 5mM Gn
SA069352ms6982-481h nonCO2 Spent Sup BGPGt 5mM Gn
SA069353ms6923-131h nonCO2 Spent Sup BGPGt 5mM Gn
SA069354ms6982-491h nonCO2 Spent Sup BGPGt 5mM Gn
SA069355ms6923-141h nonCO2 Spent Sup BGPGt 5mM Gn
SA069356ms6923-151h nonCO2 Spent Sup BGPGt 5mM Gn
SA069366ms6982-4323h +1h nonCO2 pellet BGP50uMGt Gn
SA069367ms6982-4223h +1h nonCO2 pellet BGP50uMGt Gn
SA069368ms6982-4423h +1h nonCO2 pellet BGP50uMGt Gn
SA069357ms6923-723h + 1h nonCO2 Pellet BGP50uMGt Gn
SA069358ms6923-823h + 1h nonCO2 Pellet BGP50uMGt Gn
SA069359ms6923-923h + 1h nonCO2 Pellet BGP50uMGt Gn
SA069369ms6982-3623h +1h nonCO2 pellet BGPGt 0.5mM Gn
SA069370ms6982-3823h +1h nonCO2 pellet BGPGt 0.5mM Gn
SA069371ms6982-3723h +1h nonCO2 pellet BGPGt 0.5mM Gn
SA069360ms6923-323h + 1h nonCO2 Pellet BGPGt 0.5 mM Gn
SA069361ms6923-123h + 1h nonCO2 Pellet BGPGt 0.5 mM Gn
SA069362ms6923-223h + 1h nonCO2 Pellet BGPGt 0.5 mM Gn
SA069372ms6982-4123h +1h nonCO2 pellet BGPGt 5mM Gn
SA069373ms6982-3923h +1h nonCO2 pellet BGPGt 5mM Gn
SA069374ms6982-4023h +1h nonCO2 pellet BGPGt 5mM Gn
SA069363ms6923-423h + 1h nonCO2 Pellet BGPGt 5mM Gn
SA069364ms6923-523h + 1h nonCO2 Pellet BGPGt 5mM Gn
SA069365ms6923-623h + 1h nonCO2 Pellet BGPGt 5mM Gn
SA069375ms6982-6023h Spent Sup E Med
SA069376ms6982-5823h Spent Sup E Med
SA069377ms6982-5923h Spent Sup E Med
SA069378ms6923-2623h Spent Sup E Med
SA069379ms6923-2323h Spent Sup E Med
SA069380ms6923-2423h Spent Sup E Med
SA069381ms6923-2523h Spent Sup E Med
Showing results 1 to 51 of 51
  logo